MTA1, a metastasis-associated protein, in endothelial cells is an essential molecule for angiogenesis

MIZUHO ISHIKAWA¹, MITSUHIKO OSAKI¹,², NARUMI UNO²,³, TAKAHITO OHIRA²,³, HIROYUKI KUGOH²,³ and FUTOSHI OKADA¹,²

¹Division of Experimental Pathology, ²Chromosome Engineering Research Center, ³Division of Genome and Cellular Functions, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan

Received August 5, 2021; Accepted October 14, 2021

DOI: 10.3892/mmr.2021.12527

Abstract. Our previous study revealed that metastasis-associated protein 1 (MTA1), which is expressed in vascular endothelial cells, acts as a tube formation promoting factor. The present study aimed to clarify the importance of MTA1 expression in tube formation using MTA1-knockout (KO) endothelial cells (MTA1-KO MSS31 cells). Tube formation was significantly suppressed in MTA1-KO MSS31 cells, whereas MTA1-overexpression MTA1-KO MSS31 cells regained the ability to form tube-like structures. In addition, western blotting analysis revealed that MTA1-KO MSS31 cells showed significantly higher levels of phosphorylation of non-muscle myosin heavy chain IIa, which resulted in suppression of tube formation. This effect was attributed to a decrease of MTA1/S100 calcium-binding protein A4 complex formation. Moreover, inhibition of tube formation in MTA1-KO MSS31 cells could not be rescued by stimulation with vascular endothelial growth factor (VEGF). These results demonstrated that MTA1 may serve as an essential molecule for angiogenesis in endothelial cells and be involved in different steps of the angiogenic process compared with the VEGF/VEGF receptor 2 pathway. The findings showed that endothelial MTA1 and its pathway may serve as promising targets for inhibiting tumor angiogenesis, further supporting the development of MTA1-based antiangiogenic therapies.

Introduction

Metastasis-associated protein 1 (MTA1), a member of the MTA family, was first identified by Toh et al. (1). MTA1 expression is reported to be associated with tumor malignancy in several cancer types, including esophageal, gastrointestinal, non-small-cell lung, breast and ovarian cancer (2-6). In addition, MTA1 promotes tumor cell proliferation and invasion, and tumor angiogenesis and metastasis (7-9).

However, the precise functional role of endothelial MTA1 in angiogenesis remains unclear. Our previous study examined the function of MTA1 in endothelial cells by MTA1 knockdown and found that MTA1 small interfering (si)RNA significantly inhibited tube formation but not the proliferation and migration of endothelial cells (10). In addition, it was demonstrated that MTA1 knockdown induced a decrease in S100 calcium-binding protein A4 (S100A4) expression and an increase in phosphorylated non-muscle myosin heavy chain IIa (NMIIa). This phosphorylation level of NMIIa may influence the formation of tube structures via altered cytoskeletal dynamics in endothelial cells (10). To evaluate the function of MTA1 further, it is necessary to confirm the inhibition of tube formation using MTA1-knockout (KO) cells and to evaluate whether the ability of tube formation is restored by re-expressing MTA1 in the KO cells.

In the present study, MTA1-KO endothelial cells (MTA1-KO MSS31 cells) were established and examined to clarify the role of MTA1 expression in tube formation by endothelial cells. The relationship between the inhibition of tube formation in MTA1-KO MSS31 cells and the vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) pathway was also investigated.

Materials and methods

Cell culture and reagents. Mouse endothelial cells (MSS31 cells), a gift from Dr H Endo (The University of Tokyo, Tokyo, Japan), and MTA1-KO MSS31 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F-12 medium (Nissui Pharmaceuticals Co., Ltd.) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich; Merck KGaA) at 37˚C in a humidified 5% CO2-95% air mixture. MSS31 cells and MTA1-KO MSS31 cells (3x10⁵) were transfected with 2 µg MTA1 expression vector or empty vector as a negative control provided by Dr K Takenaga (Chiba Cancer Center Research Institute, Chiba, Japan) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol at room temperature for 20 min. The transfected cells were cultured for 24 h and used in subsequent
experiments. When conducting subsequent experiments, each experiment had a non-treatment group.

**Engineering of guide (g)RNA and CRISPR-Cas9 vector for MTA1 KO.** The gRNA for MTA1 KO targeting the first exon of MTA1 on the coding strand was engineered using the online CRISPR design tool (version 1.3) (http://crispr.mit.edu/). The targeted sequence was 5'-CAGGATTTAACAGGTATAACA AG-3'. Complementary guide oligonucleotides (forward, 5'-CACCCGGAGATGAGACCTAAAC-3' and reverse, 5'-AAACTTTAGAGCTCTCAATCCTGC-3') were custom synthesized separately by Sigma-Aldrich (Merck KGaA), annealed and cloned into the BbsI site of pSpCas9(BB)-2A-GFP (pX458). pX458 was a gift from Feng Zhang (Addgene; cat. no. 48138; http://n2t.net/addgene:48138; Research Resource Identifiers (RRID; Addgene_48138)) (11).

**Electroporation and cell sorting.** MSS31 cells were harvested by trypsinization using 0.1% trypsin and counted using a hemacytometer. Thereafter, 1-2×10⁶ cells were resuspended with 3 μg plasmid DNA in 100 ml electroporation buffer, transferred to a 0.2 cm cuvette (Nepa Gene Co., Ltd.) and electroporated using a square electric pulse generating electroporator (NEPA21; Nepa Gene Co., Ltd.) with poring pulse (voltage, 150 V; pulse length, 7.5 msec; pulse interval, 50 msec; number of pulses, 2; decay rate, 10%; polarity, +) and transfer pulse (voltage, 20 V; pulse length, 50 msec; pulse interval, 50 msec; number of pulses, 5; polarity, +/−). The cells were transferred to DMEM/Ham's F-12 medium (Nissui Pharmaceuticals Co., Ltd.) supplemented with 10% FBS (Sigma-Aldrich; Merck KGaA) and seeded in 60 mm dishes. After 24 h of electroporation, the transfected populations were sorted by GFP expression using MoFlo XDP cell sorter, equipped with 488 nm blue laser (Beckman Coulter, Inc.). GFP was excited by 488 nm blue laser and its emission detected using a 529/28 Band pass (BP) filter. Single cells were sorted into 384-well microplates and cultured for >1 month to allow for colony formation.

**Genomic DNA isolation, PCR and cloning for DNA sequencing.** Genomic DNA was extracted from cells using the Gentra Puregene Cell kit (Qiagen GmbH) according to the manufacturer's instructions and PCR analyses were performed as follows. The PCR amplification of the targeted regions was performed with TaKaRa Ex Taq Hot Start (Takara Bio Inc.) using PCR gene-specific forward (5'-CTCTCTGCGCTCTG TCCATC-3') and reverse (5'-CCGGACCCACTCTCAGT CTC-3') primers. The following temperature protocol was used for PCR: 98°C for 1 min; 40 cycles of 98°C for 15 sec, 60°C for 15 sec and 72°C for 40 sec; and 72°C for 7 min. The PCR reaction mixture contained each 0.25 µM forward and reverse primer, 1.25 units Ex Taq HS polymerase (Takara Bio Inc.), 1X Ex Taq Buffer (Takara Bio, Inc.), 0.2 mM each dNTP mixture (Takara Bio, Inc.) and 50 ng genomic DNA. PCR products were directly sequenced using specific primers and cloned into the pCR™4-TOPO® TA vector (Thermo Fisher Scientific, Inc.) using the TOPO™ TA Cloning™ Kit for Sequencing, without competent cells (Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. Plasmid DNA was isolated using the PureYield™ Plasmid Miniprep System (Promega Corporation). Plasmids were sequenced using the M13 forward primer (5'-GTAAACGACGACGCTTAC-3') and M13 reverse primer (5'-CAGGAAACAGCTATGAC-3').

**Tube formation assay.** For the tube formation assay, 24-well plates were coated with Geltrix (Thermo Fisher Scientific, Inc.), which was allowed to solidify overnight at 4°C. MSS31 cells and MTA1-KO MSS31 cells (8×10⁴ cells/well) were seeded and cultured in serum-free medium or serum-free medium supplemented with VEGF-A (10 ng/ml; R&D Systems, Inc.). Tube formation was evaluated after 4, 5 or 19 h. Images of two to three random fields for each sample (magnification, x4) were captured using an all-in-One Fluorescence Microscope BZ-X710 microscope (Keyence Corporation). The number of junctions was quantified using an Angiogenesis Analyzer (developed by Gilles Carpentier) (https://imagej.nih.gov/ij/macros/tools/Angiogenesis%20Analyzer.txt) in ImageJ [version 1.52v (National Institute of Health)]. Each experiment was repeated three or four times.

**Western blotting.** Cells were washed in cold PBS and lysed in lysis buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 µg/ml aprotinin and 1 µg/ml leupeptin. Lysates were centrifuged at 13,000 x g for 5 min at 4°C. Protein concentrations were estimated using the Bradford protein assay (Bio-Rad Laboratories, Inc.) with bovine serum albumin (Fujifilm Wako Pure Chemical Co.) as the standard. Proteins were loaded 30 µg per lane and resolved by SDS-PAGE using 8, 10, 12 and 15% gels, and then electrotransferred to PVDF membranes (MilliporeSigma). After being blocked with 5% fat-free milk for 2 h at room temperature, the membranes were blotted using primary antibodies overnight at 4°C, washed using PBS with 1% Tween-20 and then incubated with secondary antibodies for 20 min at room temperature. After washing using PBS with 1% Tween-20, the bound antibodies were detected using ECL Prime Western Blotting Detection Reagent (RPN2236; Cytiva). The primary antibodies used in the present study were: Anti-MTA1 polyclonal antibody (1:2,000; cat. no. ab71153; Abcam), anti-S100A4 polyclonal antibody (1:1,000; cat. no. 07-2274; MilliporeSigma), anti-NMIAs polyclonal antibody (1:1,000; cat. no. 5026; Cell Signaling Technology, Inc.), anti-VEGFR2 polyclonal antibody (1:1,000; cat. no. 9698; Cell Signaling Technology, Inc.), anti-p-VEGFR2 (Tyr 1175) polyclonal antibody (1:1,000; cat. no. A5441; Sigma-Aldrich; Merck KGaA). The secondary antibodies used in the present study were: Goat anti-mouse IgG-HRP (1:2,000; cat. no. PM009-7; Medical and Biological Laboratories Co., Ltd.) and goat anti-rabbit IgG-HRP (1:2,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc.). Densitometry was performed using ImageJ (version 1.52v; National Institute of Health). For the western blotting for the phosphorylation of VEGFR2, wild-type MSS31 cells and MTA1-KO clones were treated with VEGF (10 ng/ml) for 30 min and were lysed in lysis buffer. For the western blotting for MTA1 expression by VEGF treatment, MSS31 cells
treated with VEGF (0, 10, 50 or 100 ng/ml) for 24, 48 or 72 h and were lysed in lysis Buffer. Each experiment was repeated three or four times.

Reverse transcription-quantitative (RT-q) PCR. Total RNA was extracted using TRizol® reagent (Thermo Fisher Scientific, Inc.) and 1 µg total RNA was reverse transcribed into cDNA using the Takara PrimeScript RT master mix (Takara Bio, Inc.) according to the manufacturer's protocol. Subsequently, 2 µl cDNA was used for quantitative PCR. qPCR was performed on a Roche LightCycler 480 (Roche Diagnostics) using SYBR Premix Ex Taq II (Tli RNaseH Plus; Takara Bio, Inc.). The primer sequences are as follows: MTA1 forward, 5'-GGCGCGATGACTGGA-3' and reverse, 5'-TTGTTTCTGGAGGAAGCAGCA-3'; and β-actin forward, 5'-AGAGGGAAATCGTGCGTGA-3' and reverse, 5'-CAATAGTGACCTGACCTGCGT-3'. The following thermocycling conditions were used for qPCR: 95°C for 30 sec; 95°C for 10 sec; followed by 45 cycles of 95°C for 10 sec and 60°C for 1 min. β-actin was used as the internal control. The results are expressed as the fold change between the expression level of each mRNA and the internal reference using the 2-ΔΔCq method (12). Each experiment was repeated three times.

Immunoprecipitation. Cells were washed in PBS and lysed in lysis buffer A [25 mM Tris-HCl (pH 7.5), 420 mM NaCl, 0.5% Triton X-100, 5 mM CaCl₂, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride (PMSF)] for 30 min at 4°C. Lysates were diluted 1.8-fold with lysis buffer B [25 mM Tris- HCl (pH 7.5), 0.5% Triton X-100, 5 mM CaCl₂, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 1 mM PMSF] and were then centrifuged at 13,000 x g for 10 min at 4°C. Immunoprecipitation assays were performed using 50 µl of the non-magnetic sepharose beads (nProtein A Sepharose beads for 1 h at 4°C. The immunoprecipitated proteins were incubated for 1 h at 4°C with 3 µg anti-MTA1 polyclonal antibody (cat. no. ab77153; Abcam), anti-S100A4 monoclonal antibody (cat. no. CPTC-S100A4-A; Developmental Studies Hybridoma Bank), normal rabbit IgG (cat. no. 2729; Cell Signaling Technology, Inc.) or normal mouse IgG (1-8765; Sigma-Aldrich; Merck KGaA). Immune complexes were recovered on nProtein G Sepharose beads or nProtein G Sepharose 4 Fast Flow or nProtein G Sepharose 4 Fast Flow; (cat. no. 17528001, 17061801; Cytiva) according to the manufacturer's instructions. Briefly, 500 µl of the supernatants containing proteins was incubated for 1 h at 4°C with 3 µg anti-MTA1 polyclonal antibody (cat. no. ab77153; Abcam), anti-S100A4 monoclonal antibody (cat. no. CPTC-S100A4-A; Developmental Studies Hybridoma Bank), normal rabbit IgG (cat. no. 2729; Cell Signaling Technology, Inc.) or normal mouse IgG (1-8765; Sigma-Aldrich; Merck KGaA). Immune complexes were washed five times with TBS [50 mM Tris-HCl (pH 7.5), 150 mM NaCl] and then 2X additional buffer [1 M Tris-HCl (pH 6.8), 10% SDS, 100% glycerol, bromophenol blue] was added. After boiling for 3 min at 95°C, the supernatants were used as western blotting samples. Western blotting was according to the aforementioned protocol. The experiment was repeated four times.

Statistical analysis. The number of samples to be analyzed was predetermined based on the requirement of the statistical test used. Statistical analysis was performed using a personal computer with the program Excel Statistics version 3.0 (Esumi Co. Ltd.) functioning on the program Excel (Microsoft Corporation). Data are shown as the mean ± standard deviation. Comparisons between two groups were analyzed using the unpaired Student’s t-test. Comparisons among multiple groups were analyzed using one-way ANOVA followed by Dunnett’s post hoc test. The researchers involved were not blinded and the samples were not randomized during sample collection or data analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

Engineering of MTA1-KO MSS31 clones. To gain deeper insight into the functions of MTA1, the present study designed gRNA targeting MTA1 and used the CRISPR-Cas9 system to generate MTA1-KO MSS31 cell lines. A total of two colonies (#1 and #2) grown from individual cells were sorted via FACS. These colonies were confirmed as MTA1 KO by RT-qPCR (data not shown) and western blotting (Fig. 1A). The deletion of MTA1 in the cellular genome of the two colonies was also checked by genome sequencing (Fig. 1B). Clone #1 had a four-base deletion in one allele and a 116-base deletion. Clone #2 had a five-base deletion in one allele and a 201-base deletion. A frameshift mutation due to multiple-base deletion in each allele resulted in the loss of wild-type MTA1 protein expression. These results indicated the successful generation of MTA1-KO MSS31 cell clones.

MTA1 expression contributes to tube formation in vitro. Previously, we reported that suppression of MTA1 in endothelial cells inhibited tube formation in vitro (10). The present study performed a tube formation assay using wild-type MSS31 cells and two MTA1-KO clones to determine the effect of tube formation in MTA1-KO clones. Images were captured of MSS31 cells and two MTA1-KO clones at 5 h after the cells were plated onto Geltrex (Fig. 2A) and analyzed using the Angiogenesis Analyzer. An example of the computer-adjusted image to evaluate tube formation and junction is shown in Fig. 2B. At 5 h after the cells were seeded, wild-type MSS31 cells showed tube formation spanning the entire well. Compared with the wild-type MSS31 cells, the two MTA1-KO clones showed significantly impaired tube formation (Fig. 2A and C).

It was also hypothesized that diminished tube formation in MTA1-KO clones could be recovered by MTA1 overexpression. After MTA1 overexpression in MTA1-KO MSS31 clones transfected with MTA1 expression vector [MTA1-KO + overexpression (OE) MSS31 clones] was confirmed by RT-qPCR and western blotting (Fig. S1A and B), a tube formation assay was performed using MTA1-KO clones and MTA1-KO + OE MSS31 clones. At 5 h after the cells were seeded, tube formation was not observed in the MTA1-KO + OE MSS31 clones (Fig. S2). At 19 h after the cells were plated onto Geltrex, short and incomplete tube-like structures were observed in MTA1-KO + OE MSS31 clones; however, no tube formation was observed in MTA1-KO clones that were transfected with empty vector or remained untransfected (Fig. 3A and B). These results indicated that the inhibition of tube formation caused by MTA1 KO was recovered by MTA1 overexpression.

Involvement of MTA1/S100A4 interaction and p-NMIa in tube formation in MTA1-KO and MTA1-KO + OE MSS31 cells. We previously reported the mechanism of tube formation
by MTA1, wherein MTA1 interacts with S100A4 and changes the phosphorylation state of NMIIa (10). Therefore, the present study examined whether inhibition of tube formation by MTA1 KO and its restoration by MTA1 overexpression was associated with the MTA1/S100A4 interaction and the phosphorylation state of NMIIa. First, the MTA1/S100A4 interaction was found to have disappeared in MTA1‑KO MSS31 cells, but was detected in MTA1‑KO + OE MSS31 cells, as determined via immunoprecipitation using anti‑MTA1 or anti‑S100A4 antibodies (Fig. 4A and B). Moreover, the phosphorylation of NMIIa was found to be increased by MTA1 KO compared with wild‑type MSS31 cells (Fig. 5A and B). The increased NMIIa phosphorylation in MTA1‑KO clones was slightly inhibited by MTA1 overexpression; however, the difference was not statistically significant (Fig. 5A and B). Thus, it was proposed that the altered tube formation abilities of MTA1‑KO and -OE cells were caused by MTA1/S100A4 interaction and NMIIa phosphorylation.

Relationship between MTA1 and VEGF in MTA1‑KO MSS31 cells. Following our previous report that MTA1 knockdown suppressed tube formation (10), the present study revealed that MTA1 knockdown also inhibited tube formation in vitro. Angiogenesis is influenced by numerous angiogenic pathways, including the VEGF‑VEGFR2 pathway (13‑15). Therefore, the present study examined whether the suppressed tube formation in MTA1‑KO MSS31 cells could be rescued by stimulation with VEGF. It was first confirmed that VEGFR2 was phosphorylated following VEGF stimulation in both wild‑type MSS31 cells and MTA1‑KO MSS31 cells (Figs. 6A, B and S3A). In addition, VEGFR2 expression levels were not notably altered by MTA1 KO. Tube formation was promoted in wild‑type MSS31 cells treated with VEGF compared with untreated cells (Figs. 6A, B and S3A). By contrast, despite the phosphorylation of VEGFR2 by VEGF treatment, tube formation could not be rescued in MTA1‑KO MSS31 cells treated with VEGF (Figs. 6A, B and S3A).
In addition, MTA1 expression was not affected by VEGF stimulation (Fig. S3B). These results indicated that VEGF stimulation could not promote tube formation in MTA1-KO MSS31 cells, implying that the role of MTA1 in tube formation may be independent of VEGF.

**Discussion**

MTA1 expression in tumor cells is reported to exert multiple functions associated with cancer progression, including proliferation, migration, invasion and tumor angiogenesis (7-9). However, the role of MTA1 in endothelial cells remains to be elucidated. Our group previously reported that MTA1 is involved in tumor angiogenesis via the MTA1/S100A4/NMIIa axis in endothelial cells (10). Therefore, the present study aimed to confirm the function of endothelial MTA1 in angiogenesis using MTA1-KO MSS31 cells generated with the CRISPR-Cas9 system.

The phosphorylation level of NMIIa was decreased in the MTA1-KO + OE MSS31 cells compared with the corresponding phosphorylation level in MTA1-KO MSS31 cells and MTA1-KO cells transfected with an empty vector. Although the protein expression level of MTA1 in MTA1-KO + OE MSS31 cells was lower than that in the wild-type MSS31 cells, the interaction between MTA1 and S100A4 occurred in a similar way to that seen in the wild-type MSS31 cells. These results indicated that low levels of MTA1 were sufficient to alter angiogenesis via the interaction with S100A4. Concerning the association between MTA1, NMIIa and tube formation, MTA1-KO MSS31 cells showed an increase in NMIIa phosphorylation and a decrease in tube formation. However, whether the level of the NMIIa phosphorylation...
directly affected the ability of tube formation was not investigated. Therefore, a mutated form of the phosphorylation site of NMIIa should be generated to investigate this further.

The present study observed that MTA1-KO MSS31 cells displayed impaired tube formation at 5 h after seeding cells and the tube structure disappeared at 19 h. By contrast, MTA1-KO + OE MSS31 cells partly formed tube-like structures at 19 h, but this was not observed at 5 h, possibly because the direct use of MTA1 expression vector-transfected cells in the tube formation assay caused differences in MTA1 expression levels among the MSS31 cells. These results indicated that endothelial MTA1 may serve an important role in tube formation and maintenance.

Angiogenesis involves multiple steps, including protease production, endothelial migration and proliferation, vascular tube formation and blood vessel maturation, that are regulated by numerous angiogenic pathways (13,16,17). A number of signaling pathways are associated with this process, whereby VEGF/VEGFR2 signaling is the most commonly known and serves as an important key pathway (14,18,19). Therefore, the present study examined the association between MTA1 and VEGF in vitro. The tube formation ability was not recovered by treatment of MTA1-KO MSS31 cells with VEGF, although the phosphorylation of VEGFR2 was confirmed in those cells treated with VEGF. These data suggested that the involvement of the MTA1/S100A4/NMIIa pathway in angiogenesis was distinct from the regulation by the VEGF/VEGFR2 signaling pathway. However, the proangiogenic factors and pathways, including the VEGF/VEGFR2 pathway and fibroblast growth factor (FGF)/FGF receptors pathway, primarily control the survival, migration and proliferation of vascular endothelial cells in previous studies (14,15,18).

The present study focused on this difference between the functions of MTA1 and VEGF in the angiogenic process. The angiogenic process can be roughly divided into two steps: Degradation of the basement membrane, proliferation, migration and sprout formation (step 1); and vascular tube formation and maturation (step 2; Fig. 7) (13,16,17). Based on this model, the VEGF/VEGFR2 signaling pathway controls the first step of the angiogenic process. Conversely, the MTA1/S100A4/NMIIa...
axis primarily regulates tube formation in the second step. In other words, MTA1 and VEGF are involved in the angiogenesis process, but the point at which they exert their functions may be different.

Tumor angiogenesis is an appealing therapeutic target (20). Antiangiogenic therapy has been applied clinically and has emerged as one of the viable treatment options for cancer (21). Due to the pivotal role of the VEGF/VEGFR2 pathway in pathological angiogenesis, most approved antiangiogenic drugs target VEGF-A or its receptors, including VEGFR2 (22,23). Although these treatment strategies have provided substantial clinical benefits in cancer therapeutics, their effects are limited by the development of resistance (24,25). The present study revealed that the MTA1/S100A4 axis in endothelial cells may serve as an important pathway for tube formation and was functionally distinct from the VEGF/VEGFR2 pathway at the site of action in angiogenesis. Thus, therapies targeting the endothelial MTA1/S100A4 axis may provide a novel therapeutic strategy distinct from conventional therapies. In other words, the axis may serve as a useful target molecule for treating patients who manifest VEGF-resistance or show poor responses to VEGF inhibitors because it may be possible to inhibit angiogenesis by blocking step 2 with or without activation of step 1 (Fig. 7). In addition, the combination of antiangiogenic drugs targeting the VEGF/VEGFR2 pathway and the MTA1/S100A4 pathway may induce additive or synergistic effects in the inhibition of tumor angiogenesis and tumor growth, resulting in improved therapeutic outcomes. These possibilities, such as the alternative for the treatment of VEGF-resistance and the enhancement of the antiangiogenic effect using VEGF inhibitors, could be the benefits of targeting the MTA1/S100A4 pathway.

However, there are problems with using MTA1 as a therapeutic target. Since MTA1 forms complexes with other proteins and regulates a number of genes, such as myeloid differentiation factor 88 and cryptochrome 1 (26,27), suppressing MTA1 itself using MTA1 inhibitors may have negative effects on other pathways. In addition, hypertension...
and impaired wound healing, which are known side effects of antiangiogenic therapy (14,28), may also occur. Therefore, suppressing MTA1 function using molecules that specifically act on the MTA1/S100A4 pathway in antiangiogenic treatment strategies targeting MTA1 is important.

The present study had several limitations. First, the investigation of the MTA1/S100A4 interaction was not complete. The present study reported that this interaction was serial (i.e., the two proteins were associated with each other) as it focused on the formation of the MTA1/S100A4 complex as a mechanism of angiogenesis. However, the possibilities that this interaction is serial, parallel (i.e., the two proteins function independently) or both should be considered. Second, the results are insufficient to definitively conclude whether MTA1 may be involved in angiogenesis regulated by the VEGF/VEGFR2 pathway. The present study demonstrated that the angiogenic process cannot occur normally if MTA1 is absent in vascular endothelial cells even when the cells were stimulated by VEGF. With only this result, the question as to how MTA1 is involved in angiogenesis compared with VEGF cannot be clearly answered. To answer these points, a screening assay should be generated to search for the candidate molecules that inhibit the formation of the MTA1/S100A4 complex. Once the candidate molecules are determined, it is expected that the MTA1/S100A4 interaction and the functions of MTA1 and VEGF in angiogenesis could be shown more clearly by comparing the results of tube formation using MTA1-KO MSS31 cells, MTA1-S100A4 inhibitors and VEGF inhibitors.

Using MTA1-KO MSS31 cells, the present study not only reconfirmed that MTA1 expression in endothelial cells served a crucial role in tube formation and that the mechanism involved the MTA1/S100A4 axis, but also demonstrated that MTA1 was functionally distinct from VEGF in its site of action in angiogenesis. These results were a novel finding and emphasized the importance of MTA1 in angiogenic process. Based on these findings and the results of our previous study (10), the MTA1/S100A4/NMIIa pathway in endothelial cells may serve as a potential target for suppressing angiogenesis and tumor growth via a mechanism of action different from that of VEGF inhibitors.

Figure 5. Changes in the phosphorylation status of NMIIa in wild-type MSS31 cells and MTA1-KO MSS31 cells transfected with the MTA1 expression vector. (A) Western blotting of wild-type MSS31 cells, MTA1-KO MSS31 cells (non-treatment), MTA1-KO cells transfected with EV and MTA1-KO cells transfected with MTA1 expression vector (MTA1-KO + OE MSS31 cells) (n=6). (B) p-NMIIa expression levels were measured using ImageJ software and normalized to β-actin (n=6). *P<0.05 vs. wild-type MSS31 cells. Data are presented as the mean ± SD. NMIIa, non-muscle myosin heavy chain Ila; MTA1, metastasis-associated protein 1; KO, knockout; OE, overexpression; EV, empty vector; non, non-treatment; p, phosphorylated.
Figure 6. Interaction between MTA1 and VEGF in MTA1-KO MSS31 cells. (A) Tube formation assays were performed using wild-type MSS31 cells and MTA1-KO clones, which were treated with VEGF or untreated. Images were captured after 4 h. Scale bar, 200 µm. (B) Quantification of the number of junctions in wild-type MSS31 cells and MTA1-KO clones. VEGF(-), n=16; VEGF(+), n=20. *P<0.05. MTA1, metastasis-associated protein 1; VEGF, vascular endothelial growth factor; KO, knockout; NS, not significant.

Figure 7. Schematic diagram of the process of tumor angiogenesis. New blood vessels are generated from pre-existing blood vessels through angiogenic growth factors secreted by tumor cells. The vascular endothelial cells in pre-existing blood vessels degrade the basement membrane, proliferate, migrate and form sprouts after the activation of angiogenic stimuli (step 1). Subsequently, these sprouts lead to vascular tube formation, followed by blood vessel maturation to complete the tube structure through which blood can flow (step 2). VEGF stimulates endothelial proliferation and migration in step 1, whereas MTA1 is primarily associated with vascular tube formation in step 2. VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor 2; PDGF, platelet-derived growth factor; bFGF, basic fibroblast growth factor; FGFR, FGF receptor; PDGFR, platelet-derived growth factor receptor; MTA1, metastasis-associated protein 1; S100A4, S100 calcium-binding protein A4.
Acknowledgements

The authors would like to thank Dr H Endo (The University of Tokyo, Tokyo, Japan) for kindly providing MSS31 cells and Dr K. Takenaga (Chiba Cancer Center Research Institute, Chiba, Japan) for providing the MTA1 expression vector.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

MI, MO, NU, TO, HK and FO designed the experiments. MI, NU, TO and MO performed the experiments and analyzed the data. MI, MO, NU, TO, HK and FO wrote, reviewed and revised the manuscript. MI, MO and NU confirm the authenticity of all the raw data. All authors reviewed and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Toh Y, Pencil SD and Nicolson GL: A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 269: 22958-22963, 1994.

2. Toh Y, Kawan H, Mori M, Nicolson GL and Sugimachi K: Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br J Cancer 79: 1723-1726, 1999.

3. Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, Nicolson GL and Sugimachi K: Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis. Int J Cancer 74: 459-463, 1997.

4. Zhu X, Guo Y, Li X, Ding Y and Chen L: Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer. J Thorac Oncol 5: 1159-1166, 2010.

5. Jang KS, Paik SS, Chung H, Oh YH and Kong G: MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci 97: 374-379, 2006.

6. Dannemann C, Shabani N, Friese K, Jeschke U, Mylonas I and Brüning A: The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERβ, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther 7: 1460-1467, 2008.

7. Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K and Moustafa A: Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: Role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis 20: 19-24, 2003.

8. Kai L, Wang J, Ivanovic M, Chung YT, Laskin WB, Schulze-Hoepfner F, Mirochnik Y, Satcher RL Jr and Levenson AS: Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1). Prostate 71: 268-280, 2011.

9. Pakala SB, Rayala SK, Wang RA, Ohshiro K, Mudvari P, Reddy SD, Zheng Y, Pires R, Casimiro S, Pillai MR, et al: MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer. Cancer Res 73: 3761-3770, 2013.

10. Ishikawa M, Osaki M, Yamagishi M, Onuma K, Ito H, Okada F and Endo H: Correlation of two distinct metastasis-associated proteins, MTA1 and S100A4, in angiogenesis for promoting tumor growth. Oncogene 38: 4715-4728, 2019.

11. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA and Zhang F: Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8: 2281-2308, 2013.

12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

13. Welti J, Loges S, Dimmel S and Carmeliet P: Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123: 3190-3200, 2013.

14. Teleau R, Chircov C, Grumelescu AM and Teleau DM: Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J Clin Med 9: E84, 2019.

15. Jászai J and Schmidt MH: Trends and challenges in tumor anti-angiogenic therapies. Cells 8: E102, 2019.

16. Rajabi M and Mousa SA: The role of angiogenesis in cancer treatment. Biomolecules 5: E34, 2017.

17. Herbert SP and Stainier DY: Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 12: 551-564, 2011.

18. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.

19. Apte RS, Chen DS and Ferrara N: VEGF in signaling and disease: Beyond discovery and development. Cell 176: 1248-1264, 2019.

20. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.

21. Jayson GC, Kerbel R, Ellis LM and Harris AL: Antiangiogenic therapy in oncology: Current status and future directions. Nat Rev Cancer 5: 947-957, 2005.

22. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005.

23. Haibe Y, Kreidich M, El Hajj H, Khalifeh I, Mukherji D, Temraz S and Shamseddine A: Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol 10: 221, 2020.

24. Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603, 2008.

25. van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Bomman A and Kumar R: MTA1 coregulator regulates LPS response via MyD88-dependent signaling. J Biol Chem 285: 32787-32792, 2010.

26. Li DQ, Pakala SB, Reddy SD, Peng S, Balasenthil S, Deng CX, Lee CC, Rea MA and Kumar R: Metastasis-associated protein 1 is an integral component of the circadian molecular machinery. Nat Commun 4: 2545, 2013.

27. Mitchell DC and Bryan BA: Anti-angiogenic therapy: Adapting strategies to overcome resistant tumors. J Cell Biochem 111: 543-553, 2010.